#1 Clinical Trials Search in Europe

Study of drug combination therapy after surgery in patients with resectable pancreatic ductal adenocarcinoma using lab-grown mini-tumors to guide treatment selection

2 1 1 1

What is this study about?

This study focuses on patients with pancreatic ductal adenocarcinoma (PDAC) who have had surgery to remove their tumor. The research aims to use laboratory-grown miniature versions of tumors, called organoids, created from patients’ cancer tissue to predict which chemotherapy treatment will work best for each individual after surgery.

The study involves several chemotherapy medications that are commonly used to treat pancreatic cancer. These include capecitabine, paclitaxel, irinotecan, gemcitabine, fluorouracil, oxaliplatin, and calcium folinate. Some medications are given by mouth, while others are administered through an intravenous line. The treatment period typically lasts for 6 months.

The research is divided into two parts. The first part checks if it’s possible to grow these mini-tumors and test different chemotherapy combinations on them within 12 weeks after surgery. The second part examines how well patients do when their treatment is chosen based on how their laboratory-grown tumor responds to different chemotherapy combinations. The effectiveness of the treatment will be measured by tracking how long patients remain free of cancer after treatment.

1 Initial participation confirmation

After pancreatic cancer surgery, your tissue sample will be used to create organoids (miniature laboratory versions of your tumor).

The organoids will be tested to determine which chemotherapy might work best in your case.

2 Medical assessment

Your doctor will check if you meet health requirements, including:

– Blood test results within specific ranges

– Kidney function showing creatinine clearance of 30 ml/min or higher

– Liver function tests within acceptable limits

– No signs of cancer spread after surgery

– General health status allowing for chemotherapy

3 Treatment initiation

Treatment must begin within 12 weeks after surgery.

Based on organoid testing results, you will receive one of these chemotherapy combinations:

– mFOLFIRINOX: combination of fluorouracil, oxaliplatin, irinotecan, and calcium folinate given through vein

– Gemcitabine: given through vein

– Capecitabine: taken as tablets

– Gemcitabine with Capecitabine: combination of both medications

4 Monitoring period

Regular check-ups will monitor your progress for at least 18 months.

You will complete quality of life questionnaires during this period.

Regular scans and blood tests will check for any signs of cancer return.

5 Safety requirements

If you can become pregnant or father a child, you must use effective birth control during treatment and for 15 months afterward.

Regular blood tests will monitor your body’s response to treatment.

Your doctor will check for and manage any side effects of the treatment.

Who Can Join the Study?

  • Must be 18 years or older
  • Must have pancreatic ductal cancer that can be surgically removed
  • Must have a Ca19-9 blood test result below 500 U/ml (Ca19-9 is a tumor marker used to monitor pancreatic cancer)
  • Must have good physical performance (ECOG score 0-1, meaning able to carry out light daily activities)
  • Must have adequate kidney function (creatinine clearance of 30 ml/min or higher)
  • Must have acceptable liver function tests:
    – Bilirubin levels between 1.5-3 times the normal limit
    – ALT and AST (liver enzymes) no more than 2.5 times the normal limit
  • Must have adequate blood cell counts:
    – White blood cells: 3.5 million or more per milliliter
    – Neutrophils (type of white blood cells): 1.5 million or more per milliliter
    – Platelets: 100 million or more per milliliter
  • Must be able to start chemotherapy within 12 weeks after surgery
  • Must have no signs of cancer spread to other organs (like liver, lung, or abdomen lining)
  • If able to have children, must agree to use effective birth control methods during treatment and for 15 months after the last treatment
  • Must provide signed informed consent to participate in the study

Who Cannot Join the Study?

  • Age below 18 years or above 75 years
  • Presence of pancreatic cancer that cannot be surgically removed
  • Ca19-9 (a blood tumor marker) level higher than 500 U/ml
  • Significant cholestasis (a condition where bile cannot flow from the liver to the small intestine)
  • Not meeting the NCCN criteria (standard guidelines for cancer treatment)
  • Unable to provide informed consent
  • Pregnancy or breastfeeding
  • Participation in other clinical trials
  • Active, uncontrolled infections
  • Serious heart, liver, or kidney conditions that could interfere with treatment
  • History of other cancers in the past 5 years (except for adequately treated non-melanoma skin cancer)
  • Mental conditions that could prevent following study procedures
  • Known allergies to study medications

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name City Country Status
Klinikum Nuernberg Nürnberg Germany
Klinikum der Technischen Universitaet Muenchen (TUM Klinikum) Munich Germany
Katholisches Klinikum Bochum gGmbH Bochum Germany
Universitaetsklinikum Tuebingen AöR Tuebingen Germany
Charite Universitaetsmedizin Berlin KöR Berlin Germany
Universitaetsklinikum Mannheim GmbH Mannheim Germany
Institut fuer Klinische Transfusionsmedizin und Immungenetik Ulm gGmbH Ulm Germany

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Germany Germany
Recruiting
09.06.2025

Trial locations

Investigated drugs:

Based on the provided data, I cannot identify any specific medications or therapies to list, as the trial information focuses on using organoids to predict treatment efficacy in pancreatic cancer patients after surgery. The data doesn’t specify any particular medications or therapeutic agents. The trial appears to be studying the feasibility of using organoid-based approaches for treatment selection rather than testing specific drugs.

Without information about the actual medications or therapies being tested, I cannot provide the requested medication descriptions.

Investigated diseases:

Pancreatic Ductal Adenocarcinoma (PDAC) – A type of cancer that begins in the cells lining the ducts of the pancreas. It develops when cells in the pancreatic ducts begin to grow uncontrollably, forming a tumor. The disease typically progresses by growing locally within the pancreas and can spread to nearby structures. PDAC can affect the pancreas’s ability to produce digestive enzymes and hormones that regulate blood sugar. The cancer cells can form masses that interfere with normal pancreatic function and may spread to other parts of the body. This type of cancer often develops gradually, and early stages may not cause noticeable symptoms.

Trial ID:
2023-510490-34-00
Protocol code:
UNITEPANC
Trial Phase:
Therapeutic exploratory (Phase II)

Other Trials to Consider

  • A Study of BMS-986504 Combined with Nab-Paclitaxel and Gemcitabine for Patients with Untreated Metastatic Pancreatic Cancer with MTAP Gene Deletion

    Recruiting

    4 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +9

  • A Study Testing BNT329 Safety and Effectiveness in Patients With Advanced Solid Tumors That Express the CA19-9 Tumor Marker

    Recruiting

    2 1 1
    Germany Spain